Human variability and susceptibility to trichloroethylene

Environmental Health Perspectives

Volumn 108, Issue SUPPL. 2, 2000, Pages 201-214

  Pastino, Gina M ^a,b   Yap, Wendy Y ^a   Carroquino, Maria ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Children; Gender differences; Human variability; Susceptibility; Trichloroethylene

Indexed keywords

ALCOHOL; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CYTOCHROME P450; ORGANOHALOGEN DERIVATIVE; SOLVENT; TRICHLOROETHYLENE;

ACUTE TOXICITY; AGE; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CHILD; CHILD DEVELOPMENT; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; ENZYME INDUCTION; ETHNIC GROUP; GENDER; GENE EXPRESSION; GLUTATHIONE METABOLISM; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; MALE; METABOLISM; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REPRODUCTION; TOXICOKINETICS;

ANIMALIA;

EID: 0033934515     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.00108s2201     Document Type: Article

References (185)

1. National Research Council. Risk Assessment in the Federal Government: Managing the Process. Washington, DC:National Academy Press, 1983.
2. National Research Council. Science and Judgment in Risk Assessment. Washington, DC:National Academy Press, 1994.
3. Sexton K, Callahan M, Bryan EF. Estimating exposure and dose to characterize health risks: the role of human tissue monitoring in exposure assessment. Environ Health Perspect 103:13-29 (1995).
4. Clean Air Act, 33 United States Code Sec. 1241 Et Esq. 1970.
5. Presidential/Congressional Commission on Risk Assessment and Risk Management. Risk Assessment and Risk Management in Regulatory Decision-Making. Final Report, Vol. 2. U.S. Government Printing Office: 1997-519348/90015.
6. Vainio H, Husgafvel-Pursiainen K. Elimination of environmental factors or elimination of individuals: biomarkers and prevention. J Occup Environ Med 37:12-13 (1995).
7. Renwick AG, Lazarus NR. Human variability and noncancer risk assessment - an analysis of the default uncertainty factor. Regul Toxicol Pharmacol 27:3-20 (1998).
8. U.S. Environmental Protection Agency. Guidelines for Risk Characterization. Washington, DC:Science Policy Council, 1995.
9. U.S. EPA. Proposed Guidelines for Carcinogen Risk Assessment. EPA/600/P-92/003C. Washington, DC:U.S. Environmental Protection Agency, 1996.
10. Barton HA, Flemming, CD, Lipscomb, JC. Evaluating human variability in chemical risk assessment: hazard identification and dose-response assessment for noncancer oral toxicity of trichloroethylene. Toxicology 111:271-287 (1996).
11. Davidson IWF, Beliles RP. Consideration of the target organ toxicity of trichloroethylene in terms of metabolite toxicity and pharmacokinetics. Drug Metab Rev 23:493-499 (1991).
12. ATSDR. Toxicological Profile for Trichloroethylene. Atlanta, GA:Agency for Toxic Substances and Disease Registry, 1993.
13. Maltoni C, Lefemine G, Cotti G, Perino G. Long-term carcinogenicity bioassays on trichloroethylene administered by inhalation to Sprague-Dawley rats and Swiss and B6C3F1 mice. Ann NY Acad Sci 534:316-342 (1988).
14. National Research Council. Pesticides in the Diets of Infants and Children. Washington, DC:National Academy Press, 1993.
15. Lash LH. Metabolism of trichloroethylene. Environ Health Perspect 108(suppl 2):177-200 (2000).
16. Swan S, Deane M, Harris J, Neutra R. Pregnancy outcomes in relation to water contamination, 1980-81, San Jose, CA. In: Pregnancy Outcomes in Santa Clara County 1980-82: Reports of Two Epidemiological Studies. Berkeley, CA:California Department of Health Services, 1985.
17. Goldberg SJ, Lebowitz D, Graver EJ, Hicks S. An association of human congenital cardiac malformations and drinking water contaminants. J Am Coll Cardiol 16:155-164 (1990).
18. Dawson B, Johnson P, Goldberg S, Ulreich J. Cardiac teratogenesis of halogenated hydrocarbons-contaminated drinking water. J Am Coll Cardiol 21:1466-1472 (1993).
19. Nartosky MG, Weller EA, Chinchilli VM, Kavlock RJ. Nonadditive developmental toxicity in mixtures of trichloroethylene, di-(2-ethylhexyl)phthalate and heptachlor in a 5 X 5 X 5 design. Fundam Appl Toxicol 27:203-216 (1935).
20. Barton HA, Clewell HC. Non-cancer effects due to trichloroethylene: pharmacokinetics and risk assessment. Environ Health Perspect 108(suppl 2):323-334 (2000).
21. U.S. EPA. Health Assessment Document for Trichloroethylene-Final Report EPA/600/8-82/006F. Washington, DC:U.S. Environmental Protection Agency, 1985.
22. Bull RJ. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ Health Perspect 108(suppl 2):241-259 (2000).
23. Lash LH. Modes of action for kidney tumorigenisis. Environ Health Perspect 108(suppl 2):225-240 (2000).
24. U.S. EPA. Addendum to the Health Assessment Document for Trichloroethylene: Updated Carcinogenicity Assessment for Trichloroethylene. EPA/600/8-82-006FA. Washington, DC:U.S. Environmental Protection Agency, 1987.
25. U.S. EPA. Addendum to the Health Assessment Document for Trichloroethylene. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office. EPA/600/8-82/006FA. External Review Draft. Research Triangle Park, NC:U.S. Environmental Protection Agency, 1998.
26. U.S. EPA. Letter from Science Advisory Board, Halogenated Organics Subcommittee, to Hon. Lee Thomas, Administrator, March 9, 1988.
27. American Conference on Governmental Industrial Hygienists. Notice of intended change - trichloroethylene. Appl Occup Environ Hyg 7:786-791 (1992).
28. Spirtas R, Stewart RA, Lee JS, Marano DE, Forbes CD, Grauman DJ, Pettigrew HM, Blair A, Hoover RN, Cohen JL. Retrospective cohort mortality study of workers at an aircraft maintenance facility. I: Epidemiological results. Br J Ind Med 48:515-530 (1991).
29. Stewart PA, Lee JS, Marano DE, Spiritas R, Forbes CD, Blair A. Retrospective cohort mortality study of workers at an aircraft maintenance facility. I: Exposures and their assessment. Br J Ind Med 48:531-537 (1991).
30. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 63: Dry Cleaning. Some Chlorinated Solvents and Other Industrial Chemicals. Lyon:International Agency for Research on Cancer, 1995.
31. Henschler D, Vamvakas S, Lammert M, Dekant W, Kraus B, Thomas B, Ulm K. Increased incidence of renal cell tumors in a cohort of cardboard workers exposed to trichloroethene. Arch Toxicol 69(5):291-299 (1995).
32. Axelson A, Sledon A, Anderson K, Hogstedt C. Updated and expanded Swedish cohort study on trichloroethylene and cancer risk. J Occup Med 36(5):556-562 (1994).
33. Blair A, Hartge P, Stewart PA, McAdams M, Lubin J. Mortality and cancer incidence of aircraft maintenance workers exposed to trichloroethylene and other organic solvents and chemicals: extended follow up. Occup Environ Med. 55(3):161-71 (1998).
34. Morgan RW, Kelsh MA, Zhao K, Heringer S. Mortality of aerospace workers exposed to trichloroethylene. Epidemiology 9(4):424-431 (1998).
35. Vamvakas S, Bruening T, Thomasson B, Lammert M, Baumueller A, Bolt HM, Dekant W, Birner G, Henschler D, Ulm K. Renal cell cancer correlated with occupational exposure to trichloroethylene. J Cancer Res Clin Oncol 124(7):374-382 (1998).
36. David NJ, Wolman R, Milne FJ, Nierkerk, I. Acute renal failure due to trichloroethylene poisoning. Br J Ind Med 46:347-349 (1989).
37. Rasmussen K, Brogen CH, Sabroe S. Subclinical affection of liver and kidney function and solvent exposure. Int Arch Occup Environ Health 64(6):445-448 (1993).
38. Anttila A, Pukkala E, Sallmen M, Hernberg S, Hemminki K. Cancer incidence among Finnish workers exposed to halogenated hydrocarbons. J Environ Occup Med 37:797-806 (1995).
39. Burg J, Gist GL. The potential impact on women from environmental exposures. J Women's Health 6(2):159-161 (1997).
40. Lipscomb JC, Garrett CM, Snawder JE. Use of kinetic and mechanistic data in species extrapolation of bioactivation: cytochrome P-450 dependent trichloroethylene metabolism at occupationally relevant concentrations. J Occup Health 40:110-117 (1998).
41. Vamvakas S, Elfarra AA, Dekant W, Henschler D, Anders MW. Mutagenicity of amino acid and glutathione S-conjugates in the Ames test. Mutat Res 206(1):83-90 (1988).
42. Lash, LH, Putt DA, Fisher JW, Brashear WT, Parker JC. Identification of S-(1,2-dichlorovinyl) glutathione in the blood of human volunteers exposed to trichloroethylene. J Toxicol Environ Health 56(1):1-21 (1999).
43. Green T. Pulmonary toxicity and carcinogenicity of trichloroethylene: species differences and modes of action. Environ Health Perspect 10B(suppl 2):261-264 (2000).
44. Venitt S. Mechanisms of carcinogenesis and individual susceptibility to cancer. Clin Chem 40:1421-1425 (1994).
45. Ommen GS. Comment: Genetics and public health. Am J Public Health 86:1701-1704 (1997).
46. Nebert DW. Polymorphism of human CYP2D genes involved in drug metabolism: possible relationship to individual cancer risk. Cancer Cells 3:93-96 (1991).
47. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet 26:59-70 (1994).
48. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391-407 (1991).
49. Poulsen E. Risk assessment for people exposed from different environments. Pharmacol Toxicol 72(S1):51-54 (1993).
50. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21 (1992).
51. Raunio H, Husgafvel-Pursiainen K, Anttila A, Hietanen E, Hirvonen A, Pelkonen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review. Gene 159:113-121 (1995).
52. Nakajima T, Wang R, Elovaara E, Park S, Harry G, Vainio H. A comparative study on the contribution of cytochrome P450 isozymes to metabolism of benzene, toluene, and trichloroethylene in rat liver. Biochem Pharmacol 43:251-257 (1992).
53. Nakajima T, Wang RS, Elovaara E, Park S, Gelboin H, Vainio H. Cytochrome P450-related differences between rats and mice in the metabolism of benzene, toluene, and trichloroethylene in liver microsomes. Biochem Pharmacol 45:1079-1085 (1993).
54. Raucy J. Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Toxicology 105:217-223 (1995).
55. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 77:517-543 (1997).
56. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3:566-573 (1990).
57. Stephens EL, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenesis 4:185-192 (1994).
58. Yoo JS, Guengerich FP, Yang CS. Metabolism of N-nitrosodialkyl-amines in human liver microsomes. Cancer Res 88:1499-1505 (1988).
59. Medinsky MA, Asgharian B, Farris GM, Gonzalez FJ, Schlosser PM, Seaton MJ, Valentine JL. Benzene risk assessment: transgenic animals and human variability. CIIT Activ 17:1-5 (1997).
60. Lipscomb JC, Mahle DA, Brashear WT, Garrett CM. A species comparison of chloral hydrate metabolism in blood and liver. Biochem Biophys Res Commun 227:340-350 (1996).
61. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamura R, Wantanabe M. Association between RFLP of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 82:254-256 (1991).
62. Ingelman-Sundberg M, Alexandrie AK, Persson I, Rannug A. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1. Regulation and toxicological implications. Pharmacol Toxicol Suppl 64 (2):S10 (1994).
63. Persson I, Johansson I, Bergling H, Dahl ML, Seidegard J, Rylandet R, Rannug A, Hogberg J, Sundberg MI. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 319:207-211 (1993).
64. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, Weston A, Harris CC. Cytochrome P45IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 52:6712-6715 (1992).
65. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vanio H. The human CYP2E1 gene and lung cancer: Oral and Rsal restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 14 (1):85-88 (1992).
66. Wantanabe J, Yang JP, Eguchi H, Hayashi S, Imai K, Nakachi K, Kawajiri K. An RSAI polymorpbism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jpn J Cancer Res 86:245-248 (1995).
67. Hilldesheim A, Chen CJ, Caporaso NE. Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: Results from a case-control study conducted in Taiwan. Cancer Epidemiol Biomarker Prev 4(6):607-610 (1995).
68. U.S. Department of Health and Human Services. Ninth Special Report to the Congress Alcohol and Health, 1997. NIH Publication No. 97-4017. Bethesda MD National Institute of Alcohol Abuse and Alcoholism, 1997.
69. Thomasson HR, Edenberg HJ, Crabb OW, Li XL, Jerome RE, Li TK, Wang SP, Lin YT, Lu RB, Yin SJ. Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. Am J Hum Genet 48:677-681 (1991).
70. Agarwal DP, Goedde HW. Pharmacogenetics of alcohol metabolism and alcoholism. Pharmacogenetics 2(2):48-62 (1992).
71. Edman K, Maret W. Alcohol dehydrogenase genes, restriction fragment length polymorphisms for ADH4 (p-ADH) and ADH5 (c-ADH) and construction of haplo types among different ADH classes. Hum Genet 90:395-401 (1992).
72. Yoshida A. Molecular genetics of human aldehyde dehydrogenase. Pharmacology 2:139-147 (1992).
73. Yoshida A, Hsu LC, Yasunami M. Genetics of human alcohol-metabolizing enzymes. Prog Nucleic Acid Res 40:255-287 (1991).
74. Morena A, Pares A, Ortiz J, Enriquez J, Pares X. Alcohol dehydrogenase from human stomach: variability in normal mucosa and effect of age, gender, ADH3 phenotype and gastric region. Alcohol Alcohol 29(6):663-671 (1994).
75. Hobbs WR, Rall TW, Verdoorn TA. Hypnotics and sedatives: ethanol. In: The Pharmacological Basis of Therapeutics (Hardman JG, ed). New York:McGraw Hill, 1996:390.
76. Jaffe DR, Gandolfi AJ, Nagle RB. Chronic toxicity S-(trans-1,2-dichlorovinyl)-L-cysteine in mice. J Appl Toxicol 4(6):315-319 (1984).
77. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85(14):1159-1164 (1993).
78. Daly AK, Thomsa DJ, Cooper J, Pearson WR, Neal DE, Idle JR. Homozygous deletion of a gene for glutathione S-transferase M1 in bladder cancer. Br Med J 307:481-482 (1993).
79. Nazar-Stewart V, Motulsky AG, Eaton DL, White E, Hornung SK, Leng ZT, Stapteton P, Weiss NS. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 53(suppl 10):2313-2318 (1993).
80. Heagerty AH, Fitzgerald D, Smith A, Bowers B, Jones P, Fryer AA, Zhao L, Alldersea J, Strange RC. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumors. Lancet 343:266-268 (1994).
81. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14(9):1821-1824 (1993).
82. Peters WH, Nagengast FM, Wobbes T. Glutathione S-transferases in normal and cancerous human colon tissue. Carcinogenesis 10(12):2371-2374 (1989).
83. Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK, Hardy S. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 15(5):1077-1081 (1994).
84. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bol: HM, Ketterer B, Taylor JB. Human glutathione S-transferase θ (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300(1):271-276 (1994).
85. Lee EJ, Wong JY, Yeoh PN, Gong NH. Glulathione S transferase-θ (GSTT1) genetic polymorphism among Chinese, Malays and Indians in Singapore. Pharmacogenesis 5(5):332-334 (1995).
86. Nelson HH, Wiencke JK, Christiani OC, Chieng TJ, Zuo ZF, Schwartz BS, Lee BK, Spitz M, Wang M, Xu XP, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase θ. Carcinogenesis 16(5):1243-1245 (1995).
87. Schroder KR, Wiebel FA, Reich S, Dannappel D, Bolt HM, Hallier E. Glutathione-S-transferase (GST) θ polymorphism influences background SCE rate. Arch Toxicol 69(7):505-507 (1995).
88. Wiencke JK, Pemble S, Ketterer B, Kelsey KT. Gene deletion of glutathione-S-transferase θ: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomark Prev 4(3)253-259 (1995).
89. Bruning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM. Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch Toxicol. 71(9):596-599 (1997).
90. Kelsey KT, Spitz MR, Zuo ZF, Wiencke JK. Polymorphisms in the glutathione S-transferase class μ and θ genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States). Cancer Causes Control 8(4):554-559 (1997).
91. Shimada T, Yamazaki H, Mumura M, Inui U, Guenger ch FP. Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423 (1994).
92. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 88(3-4):183-192 (1996).
93. Long W, Tate RB, Neuman M, Manfreda J, Becker AB, Anthonisen NR. Respiratory symptoms in a susceptible population due to burning of agricultural residue. Chest 113(2):351-357 (1998).
94. Xu X, Li B, Wang L. Gender difference in smoking effects on adult pulmonary function. Eur Respir J 7(3):477-483 (1994).
95. Guinee DG Jr, Travis WD, Trivers GE, De Benedett VM, Cawley H, Welsh JA, Bennett WP, Jett J, Colby TV, Tazaelaar H, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-ergB-2 expression. Carcinogenesis 16(5):993-1002 (1995).
96. Chen Y, Horne SL, Dosman JA. Increased susceptibility to lung dysfunction in female smokers. Am Rev Respir Dis 143:1224-1230 (1991).
97. Britt EJ, Shelhamer J, Menkes H, Cohen B, Meyer M, Permutt S. Sex differences in the decline of pulmonary function with age. Chest 80(1):79-80 (1981).
98. Lash LH, Xu Y, Elfarra AA, Duescher RJ, Parker JC. Glutathione-dependent metabolism of trichloroethylene in isolated liver and kidney cells of rats and its role in mitochondrial and cellular toxicity. Drug Metab Dispos 23(8):846-853 (1995).
99. Bois FY. Statistical analysis of fisher et al. PBPK model of trichloroethylene kinetics. Environ Health Perspect 108(suppl 21:275-282 (2000).
100. Dawson B, Johnson P, Goldberg S, Ulreich J. Cardiac teratogenesis of trichloroethylene and dichloroethylene in mammalian model. J Am Coll Cardiol 16:1304-1309 (1990).
101. Bove FJ, Fulcomer MC, Klotz JB, Esmart J, Dufficy EM, Savrin JE. Public drinking water contamination and birth outcomes. Am J Epidemiol 141:850-862 (1995).
102. Avery GB, Randolf JG, Weaver T. Gastric acidity during the first day of life. Pediatrics 37:1005-1007 (1966).
103. Morselli PL. Clinical pharmacokinetics in neonates. Clin Pharmacokinet 1:81-89 (1976).
104. Seigner E, Fridrich B. Gastric emptying in newborns and young infants. Acta Ped Scand 64:525-530 (1975).
105. Crom WR. Pharmacokinetics in the child. Environ Health Perspect 102:111-118 (1994).
106. Guzelian PS, Henry CJ, Olin SS, eds. Similarities and Differences Between Children: Implications for Risk Assessment. Washington, DC:ILSI Press, 1992;32.
107. Snodgrass WR. Physiological and biochemical differences between children and adults as determinants of toxic response to environmental pollutants. In: Similarities and Differences Between Children and Adults; Implications for Risk Assessment (Guzelian PS, Henry CJ, Olin SS, eds). Washington, DC:ILSI Press, 1992;35-42.
108. Ehrnebo M, Agurell S, Jalling B, Boreus L. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol 3:189-193 (1971).
109. Herngren L, Ehrnebo M, Borehus IO. Drug binding to plasma proteins during human pregnancy and in the perinatal period. Dev Pharmacol Ther 6:110-124 (1983).
110. Friis-Hansen B. Body composition during growth: biochemical data and in vivo measurements. Pediatrics 47:264-274 (1971).
111. Friis-Hansen B. Body water compartment changes in children: changes during growth and related changes in body composition. Pediatrics 28:169-181 (1961).
112. Milsap RL, Hill MP, Szefler SJ. Special pharmacokinetic considerations in children. In: Applied Pharmacokinetics: Principles of Therapeutics, 3rd ed. (Evans WE, Schentag JJ, Jusko WJ, eds). Spokane, WA:Applied Therapeutics, 1992.
113. Carpenter SP, Lasker, JM, Raucy, JL. Expression, induction and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in the human fetal and liver hepatocytes. Mol Pharmacol 49(2):260-268 (1996).
114. Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ, Boobis AR, Raunio H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 51:403-411 (1996).
115. Hakkola J, Raunio H, Purkunen R, Pelkonen O, Saarikoski S, Cresteil T, Pasanen M. Detection of cytochrome P450 gene expression in human placenta in first trimester pregnancy. Biochem Pharmacol 52:379-383 (1996).
116. Hakkola J, Pasanen M, Pelkonen O, Evisalmi S, Anttila S, Rane A, Mantyla M, Hukkanen J, Purkunen R, Saarikoski S, et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis 18:391-397 (1997).
117. Boutelet-Bochan, Huang Y, Juchau MR. Expression of CYP2E1 during embryogenesis and fetogenesis in human cephalic tissues: implications for the fetal alcohol syndrome. Biochem Biophys Res Commun 238:443-447 (1997).
118. Vieira I, Sonnier M, Cresteil T. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during neonatal period. Eur J Biochem 238:476-483 (1996).
119. Jones SM, Boobis AR, Moore GE, Stanier PM. Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver. Biochem Pharmacol 43:1876-1879 (1992).
120. Song B-J, Gelboin HV, Park S-S, Yang CS, Gonzales FJ. Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P450a: transcriptional and post-transcriptional regulation of the rat enzyme. J Biol Chem 261:16689-16697 (1986).
121. Peng HM, Porter TD, Ding XX, Coon MJ. Differences in the developmental expression of rabbit cytochromes P450 2E1 and 2E2. Mol Pharmacol 40:58-62 (1991).
122. Routledge PA. Pharmacokinetics in children. J Antimicrob Chemother 24:19-24 (1994).
123. Pikkarainen P, Raiha N. Development of ADH activity in the human liver. Pediatr Res 1:165-168 (1967).
124. Reimche LD, Sankaran K, Hindmarsh KW, Kasian GF, Gorecki DK, Tan L. Chloral hydrate sedation in neonates and infants - clinical and pharmacologic considerations. Dev Pharmacol Ther. 12(2):57-64 (1989).
125. Waxman DJ, Dannan GA, Guengerich FP. Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry 24(16):4409-4417 (1985).
126. Kamataki T. Purification and regulation of forms of cytochrome P-450 present specifically in liver microsomes of male and female rats. Yakugaku Zasshi 105(7):607-618 (1985).
127. Murphy GM, Signer E. Progress report: bile acid metabolism in infants and children. Gut 15:151-163 (1974).
128. Schwartz GJ, Haycock GB, Edelman, CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine clearance. Pediatrics 58:259-263 (1976).
129. Fisher JW, Mahle D, Bankston L, Greene R, Gearheart J. Lactational transfer of chemicals in breast milk. Am Ind Hygiene Assoc J 58:425-431 (1997).
130. Fisher JW, Whittaker TA, Taylor DH, Clewell HJ, Andersen ME. Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichloroethylene and its metabolite, trichloracetic acid. Toxicol Appl Pharmacol 102:497-513 (1989).
131. Raucy J, Kraner J, Lasker J. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol 23:1-20 (1993).
132. Lieber CS. Ethanol metabolism anc cirrhosis and alcoholism. Clin Chem Acta 257:59-84 (1997).
133. Hobbs WR, Rall TW, Verdoon TA. Hypnotics and sedatives; ethanol. In: the Pharmacological Basis of Therapeutics, Ninth ed. New York:MCGraw Hill, 1996:377.
134. LaPort RE, Matsushima M, Chang Y. Diabetes in America. In: Diabetes in America (Harris MI, ed). Bethesda, MD:National Institutes of Diabetes and Digestive and Kidney Diseases, 1995;37-46.
135. Kerny SJ, Aubert RE, Geiss LS. Diabetes in America. In: Diabetes in America (Harris MI, ed). Bethesda, MD:National Institute of Diabetes and Digestive and Kidney Diseases, 1995;47-67.
136. Gist GL, Burg JR. Trichloroethylene: a review of the literature from a health effects perspective. Toxicol Ind Health 11:253-306 (1995).
137. vonWartburg JP. The metabolism of alcohol dehydrogenase in normal and alcoholics: enzymes. In: The Biology of Alcoholism, Vol 1 (Kissin B, Begleiter, H, eds). New York:Plenum Press, 1971;1-29.
138. Lieber CS. The metabolism of ethanol. In: Metabolic Aspects of Alcoholism (Leber CS, ed). Baltimore, MD:Baltimore University Park Press, 1977:1-29.
139. Crabb DW, Bosron W, Li T. Ethanol metabolism Pharmacol Ther 34:59-73 (1987).
140. Lasker JM, Reucy J, Kubota S, Bloswick BP, Black M, Lieber CS. Purification and characterization of human liver cytochrome P450. Biochem Biophys Res Commun 148(1):232-238 (1987).
141. Inatomi N, Kato S, Ito D, Lieber CS. Role of peroxisomal fatty acid betaoxidation in ethanol metabolism. Biochem Biophys Res Commun 163:418-423 (1989).
142. Nakajima T, Okino T, Okuyama S, Kaneko T, Yonekura I, Sato A. Ethanol-induced enhancement of trichloroethylene metabolism and hepatotoxicity: difference from the effect of phenobarbital. Toxicol Appl Pharmacol 94:227-237 (1988).
143. Kaneko T, Yang PY, Sato A. Enzymes induced ty ethanol differently affect the pharmacokinetics of trichloroethylene and 1,1,1-trichloroethane. Occup Erviron Med 51:113-119 (1994).
144. Okino T, Nakajima T, Nakano M. Morphological and biochemical analyses of trichloroethylene hepatotoxicity: differences in ethanol- and phenobarbital-pretreated rats. Toxicol Appl Pharmacol 108:379-389 (1991).
145. Sato A, Nakajima T, Koyama Y. Interaction between ethanol and carbohydrate on the metabolism in rat liver of aromatic and chlorinated hydrocarbons. Toxicol Appl Pharmacol 68:242-249 (1983).
146. Barret L, Faure J, Guilland B, Chomat D, Didier B, Debru JL. Trichloroethylene occupational exposure: elements for better prevention. Int Arch Occup Environ Health 53(4) 283-289 (1984).
147. Muller G, Spassowski M, Henschler D. Metabolism of trichloroethylene in man. III: Interactions with ethanol. Arch Toxicol 33:173-189 (1975).
148. Sato A, Nakajima T, Koyama Y. Dose-related effects of a single dose of ethanol on the metabolism in rat liver of some aromatic and chlorinated hydrocarbons. Toxicol Appl Pharmacol 60:8-15 (1981).
149. Jakobson I, Holmberg B, Ekner A. Venous blood levels of inhaled trich oroethylene in female rats and changes induced by interacting agents. Acta Pharmacol Toxicol 59 135-143 (1986).
150. Kawamoto T, Hobara T, Kobayash H, Iwamoto S, Sakai T, Takano T, Miyazaki Y. The metabolite ratio as a function of chloral hydrate dose and intracellular redox state in the perfused rat liver. Phamacol Toxicol 60(5):325-329 (1987).
151. Larson J, Bull R. Effect of ethanol on the metabolism of trichloroethylene. J Toxicol Environ Health 28:395-406 (1989).
152. Yuki T, Thurman RG. The swift increase in alcohol metabolism. Time course for the increase in hepatic oxygen uptake and the involvement of glycolysis. Biochem J 1869 (1):119-126 (1980).
153. Sellers EM, Lang M, Koch-Weser J, LeBlanc E, Kalant H. Interaction of chloral hydrate and ethanol in man: I. Metabolism. Clin Pharmacol Ther 13:37-49 (1972).
154. Sato A, Endoch K, Kaneko T, Johanson G. Effects of consumption of ethanol on the biological monitoring of exposure to organic solvent vapors a simulation study with trichloroethylene. Br J Ind Med 48:548-556 (1991).
155. Fisher JW, Allen BC. Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models. Risk Anal 13(1):87-95 (1993).
156. Fernandez-Checa JC, Garcia-Ruiz C, Ookhtens M, Kaplowitz N. Impaired uptake of glutathione by hepatic mitochondria from chronic ethanol-fed rats. Tracer kinetic studies in vitro and in vivo and susceptibility to oxidant stress. J Clin Invest 87(2):397-405 (1991).
157. Garcia-Ruiz C, Morales A, Sallesta A, Rodes J, Kaplowitz N, Fernandez-Checa JC. Effect of chronic ethanol feeding on glutathione and functional integrity of mitochondria in periportal and perivenous rat hepatocytes. J Clin Invest 94(1):193-201 (1994).
158. Norton R, Batey R, Dwyer T, MacMahon S. Alcohol consumption and the risk of alcohol related cirrhosis in women. Br J Med 295:80-82 (1987).
159. Rabinowitz M, Van Theil DH, Dindzans V, Gavaler JS. Endoscopic findings in alcoholic liver disease: does gender make a difference? Alcohol 6:465-468 (1989).
160. Urbano-Marques A, Estruch R, Fernandez-Sola J, Nichols JM, Pare, JC, Rubin MD. The greater risk of cardiomyopathy and myopathy in women compared to men. J Am Med Assoc 274:149-154 (1995).
161. Bowlin SJ, Leske MC, Varma A, Nasca P, Weinstein A, Caplan L. Breast cancer risk and alcohol consumption. Int J Epidemiol 26:915-923 (1997).
162. Jones BM, Jones MR. Male and female intoxication levels for three alcohol doses, or, do women really get higher than men? Alcohol Tech Rep 5:11-14(1976).
163. Frezza A, DiPadova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women: role of decreased gastric alcohol dehydrogenase activity and first pass metabolism of ethanol. N Engl J Med 322:95-99 (1990).
164. Smith MK, Randall JL, Read EJ, Stober JA. Teratogenic activity of trichloracetic acid in the rat. Teratology 40:445-451 (1989).
165. Scheneker S. Fetal alcohol syndrome: current status of pathogenesis. Alcohol Clin Exper Res 14:635-643 (1990).
166. Wu D, Cederbaum A. Ethanol consumption by the nursing mother induces cytochrome P-4502E1 in neonatal rat liver. J Pharmacol Exp Ther 267:560-567 (1993).
167. Chhabra SK, Perella C, Anderson LM. Induction of hepatic and renal P4502E1 of neonatal rats exposed translactationally to ethanol. Food Chem Toxicol 34(5):469-476 (1996).
168. Binkiewicz AR, Senior B. Pseudo-Cushing syndrome caused by alcohol in breast milk. J Pediat 93:966-967 (1978).
169. Rasheed A, Mines R, McCarver-May D. Variation in induction of human placental CYP2E1: possible role in susceptibility to feta alcohol syndrome? Toxicol Appl Pharmacol 144:396-400 (1997).
170. Carpenter SP, Lasker JM, Rauch JL. Expression, induction and catalytic activity of ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocyles. Mol Pharmacol 49: 260-268 (1996).
171. Abel EL. An update on incidence of FAS: FAS is not an equal opportunity birth defect. Neurotoxicol Teratol 17(4):437-443 (1995).
172. Department of Health and Human Services. Over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use. Required alcohol warning. (Food and Drug Administration, ed). Fed Reg 62:61041-61057 (1997).
173. Gonzalez-Leon A, Schultz IR, Bull RJ. Pharmacokinetics and metabolism of dichloroacetic acid in the F344 rat after prolonged administration in drinking water. Toxicol Appl Pharmacol 146:189-195 (1997).
174. Nakajima T, Wang RS. Induction of cytochrome P450 by toluene. Int J Biochem 26(12):1333-1340 (1994).
175. Chambers HF, Sande MA. Antimicrobial agents. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics, Ninth ed. New York:McGraw-Hill, 1996;1029-1056.
176. Adami HO, Chow WH, Nyrene O, Berne C, Linet MS, Ekbom A, Wolk A, McLaughlin JK, Fraumeni JF. Excess risk of primary liver cancer in patients with diabetes melllitus. J Natl Cancer Inst 88:1472-1477 (1996).
177. LaVecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 70:950-953 (1994).
178. Wideroff L, Gridley G, Mellemkjaer L, Chow HH, Linet M, Keehn S, Borch-Johnson K, Olsen JH. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360-1365 (1997).
179. Yu MC, Long MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 83:1820-1826 (1991).
180. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism 38(11):1124-1144 (1989).
181. Whitehouse S, Cooper RH, Handle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halo-genated carboxylic acids. Biochem J 141(3):761-774 (1974).
182. Henderson GN, Curry SH, Derendorf H, Wright EC, Stacpoole PW. Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol 37(5):416-425 (1997).
183. Fisher JW, Mahle D, Abbas R. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. Toxicol Appl Pharmacol 152:339-359 (1998).
184. Barnes DG, Dourson M. Reference dose (RfD): description and use in health risk assessment. Regul Toxicol Pharmacol 8(4):471-486 (1988).
185. Khoury MJ, Genetics Working Group. From genes to public health: the applications of genetic technology in disease prevention. Am J Public Health 86:1717-1722 (1997).